Urol. praxi, 2015; 16(1): 21-24

Non-invasive non-surgical therapy in Peyronie‘s disease

MUDr.Libor Zámečník, Ph.D., FEBU, FECSM
Urologická klinika VFN a 1. LF UK, Praha

Peyronie disease is a common cause of penile deformity and sexual dysfunction. Although surgery is regarded as the definitive management

for this condition, there are many medical and minimally invasive therapies available, with widely varying efficacy reported in the literature.

The purpose of this review is to describe the current state for each of the most commonly used methods of non-surgical treatments.

Keywords: penile plastic induration, Peyronie‘s disease, non-surgical therapy

Published: March 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zámečník L. Non-invasive non-surgical therapy in Peyronie‘s disease. Urol. praxi. 2015;16(1):21-24.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med. 2010; 7(7): 2359-2374. Go to original source... Go to PubMed...
    2. Arafa M, Eid H, El-Badry A, et al. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007; 19(2): 213-217. Go to original source...
    3. Kendirci M, Trost L, Sikka SC, et al. Diabetes mellitus is associated with severe Peyronie's disease. BJU Int. 2007; 99(2): 383-386. Go to original source... Go to PubMed...
    4. Hauck EW, Hauptmann A, Haag SM, et al. New Insights into the Etiological Pathogenesis of Peyronie's Disease. Aktuelle Urol. 2003; 34(6): 387-391. Go to original source... Go to PubMed...
    5. Sommer F, Schwarzer U, Wassmer G, et al. Epidemiology of Peyronie's disease. Int J Impot Res. 2002; 14(5): 379-383. Go to original source...
    6. Schwarzer U, Sommer F, Klotz T, et al. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001; 88(7): 727-730. Go to original source... Go to PubMed...
    7. Levine LA, Estrada CR, Storm DW, et al. Peyronie disease in younger men: characteristics and treatment results. J Androl. 2003; 24(1): 27-32. Go to PubMed...
    8. Gur S, Limin M, Hellstrom WJ. Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options. Expert Opin Pharmacother. 2011; 12(6): 931-944. Go to original source... Go to PubMed...
    9. Hashimoto K, Hisasue S, Kato R, et al. Outcome analysis for conservative management of Peyronie's disease. Int J Urol. 2006; 13(3): 244-247. Go to original source...
    10. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. 2007; 178(4 Pt 1): 1398-1403; discussion 1403. Go to original source... Go to PubMed...
    11. Paulis G, Brancato T, D'Ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology. 2013; 1(1): 120-128. Go to original source... Go to PubMed...
    12. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int. 2003; 91(6): 522-524. Go to original source... Go to PubMed...
    13. Hellstrom WJ. Medical management of Peyronie's disease. J Androl. 2009; 30(4): 397-405. Go to original source... Go to PubMed...
    14. Trost LW, Gur S, Hellstrom WJ. Pharmacological Management of Peyronie's Disease. Drugs. 2007; 67(4): 527-545. Go to original source... Go to PubMed...
    15. Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol. 1959; 81(6): 770-772. Go to original source... Go to PubMed...
    16. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005; 47 (4): 530-535; discussion 535-536. Go to original source... Go to PubMed...
    17. Mynderse LA, Monga M. Oral therapy for Peyronie's disease. Int J Impot Res. 2002; 14(5): 340-344. Go to original source...
    18. Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992; 70(6): 648-651. Go to original source... Go to PubMed...
    19. Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999; 162(6): 2003-2005. Go to original source... Go to PubMed...
    20. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001; 88(1): 63-67. Go to original source... Go to PubMed...
    21. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004; 16(3): 238-243. Go to original source...
    22. Cavallini G, Biagiotti G, Koverech A, et al. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 2002; 89(9): 895-900. Go to original source... Go to PubMed...
    23. Safarinejad MR, Asgari MA, Hosseini SY, et al. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int. 2010; 106(2): 240-248. Go to original source... Go to PubMed...
    24. Smith JF, Shindel AW, Huang YC, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl. 2011; 13(2): 322-325. Go to original source...
    25. Levine LA, Latchamsetty KC. Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate. Int J Impot Res. 2002; 14(6): 478-482. Go to original source...
    26. Palmieri A, Imbimbo C, Creta M, et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012; 35(2): 190-195. Go to original source...
    27. Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010; 22(5): 298-309. Go to original source...
    28. Safarinejad MR. Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: A prospective, randomized, double-blind placebo-controlled study. J Sex Med. 2009; 6(6): 1743-1754. Go to original source... Go to PubMed...
    29. De Moura AC, Pinhiero JE. Peyronie's disease (penis plasticus); treatment by local injections of corticosteroids. J Med (Oporto). 1958; 36(799): 128-129. Go to PubMed...
    30. Serefoglu EC, Hellstrom WJ. Treatment of Peyronie's disease: 2012 update. Curr Urol Rep. 2011; 12(6): 444-452. Go to original source... Go to PubMed...
    31. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol. 1994; 151(6): 1522-1524. Go to original source... Go to PubMed...
    32. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology. 1998; 51(4): 620-626. Go to original source... Go to PubMed...
    33. Shirazi M, Haghpanah AR, Badiee M, et al. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009; 41(3): 467-471. Go to original source... Go to PubMed...
    34. Mehrsai AR, Namdari F, Salavati A, et al. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease. Andrology. 2013; 1(1): 129-132. Go to original source... Go to PubMed...
    35. Cavallini G, Biagiotti G, Lo Giudice C. Association between Peyronie disease and low serum testosterone levels: detection and therapeutic considerations. J Androl. 2012; 33(3): 381-388. Go to original source... Go to PubMed...
    36. Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. J Sex Med. 2012; 9(1): 288-295. Go to original source... Go to PubMed...
    37. Inal T, Tokatli Z, Akand M, et al. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology. 2006; 67(5): 1038-1042. Go to original source... Go to PubMed...
    38. Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol. 2006; 176(1): 394-398. Go to original source... Go to PubMed...
    39. Trost LW, Ates E, Powers M, et al. Outcomes of intralesional interferon-alpha2B for the treatment of Peyronie disease. J Urol. 2013; 190(6): 2194-2199. Go to original source... Go to PubMed...
    40. Jordan GH, Carson CC, Lipshultz LI. Minimally invasive treatment of Peyronie's disease: evidence-based progress. BJU Int. 2014; 114(1): 16-24. Go to original source... Go to PubMed...
    41. Honig SC. Intralesional collagenase in the treatment of Peyronie's disease. Ther Adv Urol. 2014; 6(2): 47-53. Go to original source...
    42. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res. 1982; 10(3): 135-140. Go to original source...
    43. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008; 5(1): 180-187. Go to original source... Go to PubMed...
    44. Gelbard M, Hellstrom WJ, McMahon CG, et al. Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease. J Sex Med. 2013; 10(11): 2822-2831. Go to original source... Go to PubMed...
    45. Martin DJ, Badwan K, Parker M, et al. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002; 168(6): 2483-2485. Go to original source... Go to PubMed...
    46. Fitch WP, 3rd, Easterling WJ, Talbert RL, et al. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease-a placebo-controlled pilot study. J Sex Med. 2007; 4(2): 477-484. Go to original source... Go to PubMed...
    47. Riedl CR, Plas E, Engelhardt P, et al. Iontophoresis for treatment of Peyronie's disease. J Urol. 2000; 163(1): 95-99. Go to original source... Go to PubMed...
    48. Montorsi F, Salonia A, Guazzoni G, et al. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J Androl. 2000; 21(1): 85-90. Go to original source... Go to PubMed...
    49. Mulhall JP, Hall M, Broderick GA, et al. Radiation therapy in Peyronie's disease. J Sex Med. 2012; 9(5): 1435-1441. Go to original source... Go to PubMed...
    50. Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol. 2009; 56(2): 363-369. Go to original source... Go to PubMed...
    51. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med. 2008; 5(6): 1468-1473. Go to original source... Go to PubMed...
    52. Gontero P, Di Marco M, Giubilei G, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med. 2009; 6(2): 558-566. Go to original source... Go to PubMed...
    53. Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012; 187(6): 2268-2274. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.